Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus

BACKGROUND: Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Han, Lu, Zhou, Jian, Zhou, Keshu, Zhu, Xinghu, Zhao, Lingdi, Fang, Baijun, Yin, Qingsong, Wei, Xudong, Zhou, Hu, Li, Linlin, Xu, Bengling, Zhang, Jishuai, Song, Yongping, Gao, Quanli
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7430488/
https://ncbi.nlm.nih.gov/pubmed/32792360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000927
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares